. 2019 May 6;78(7):633–640. doi: 10.1093/jnen/nlz032

TABLE 3.

Patient Progression-Free Survival and MGMT Methylation Levels

MGMT Methylation Level	N _above/N_below	HR	HR ^a (95% CI)	Harrell’s C	Gönen-Heller
Continuous	–	0.97	0.97 (0.96, 0.98)^***	0.64	0.61
2–100 versus 0–1	221/5	0.33	0.32 (0.12, 0.78)^*	0.51	0.51
5–100 versus 0–4	154/72	0.37	0.36 (0.26, 0.50)^***	0.59	0.60
10–100 versus 0–9	117/109	0.42	0.40 (0.30, 0.54)^***	0.61	0.60
15–100 versus 0–14	99/127	0.45	0.43 (0.32, 0.58)^***	0.60	0.59
20–100 versus 0–19	79/147	0.46	0.44 (0.32, 0.61)^***	0.59	0.58
25–100 versus 0–24	64/162	0.48	0.47 (0.34, 0.66)^***	0.57	0.56

Abbreviations: N_above, number of patients with MGMT methylation level above the cut-point; N_below, number of patients with MGMT methylation level below the cut-point; HR, mortality/tumor progression hazard ratio; CI, confidence interval.

Adjusted for age and performance level.

p < 0.05, ***p < 0.001.